T
49.87
1.43 (2.95%)
| Previous Close | 48.44 |
| Open | 49.71 |
| Volume | 746,678 |
| Avg. Volume (3M) | 2,164,449 |
| Market Cap | 5,424,224,256 |
| Price / Sales | 302.64 |
| Price / Book | 18.30 |
| 52 Weeks Range | |
| Earnings Date | 25 Mar 2026 |
| Diluted EPS (TTM) | -1.08 |
| Total Debt/Equity (MRQ) | 0.38% |
| Current Ratio (MRQ) | 30.89 |
| Operating Cash Flow (TTM) | -71.66 M |
| Levered Free Cash Flow (TTM) | -44.95 M |
| Return on Assets (TTM) | -22.15% |
| Return on Equity (TTM) | -32.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Terns Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
0.5
| Analyst Consensus | 2.0 |
| Insider Activity | -3.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.50 |
|
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.28% |
| % Held by Institutions | 100.24% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Capitolis Liquid Global Markets Llc | 31 Dec 2025 | 3,045,200 |
| Holocene Advisors, Lp | 31 Dec 2025 | 2,775,493 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BURROUGHS AMY L. | - | 46.07 | -14,583 | -671,839 |
| Aggregate Net Quantity | -14,583 | |||
| Aggregate Net Value ($) | -671,839 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 46.07 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BURROUGHS AMY L. | Officer | 16 Mar 2026 | Automatic sell (-) | 14,583 | 46.07 | 671,839 |
| BURROUGHS AMY L. | Officer | 16 Mar 2026 | Option execute | 14,583 | - | - |
| Date | Type | Details |
|---|---|---|
| 02 Feb 2026 | Announcement | Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) |
| 07 Jan 2026 | Announcement | Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference |
| 02 Jan 2026 | Announcement | Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |